COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
The purpose of this study is to find out if an investigational product called LN-145 is safe to give to participants with recurrent and/or metastatic cervical cancer and if processing tumors to obtain cells in a central lab works. LN-145 is also called tumor infiltrating lymphocytes (TILs). TILs are generated by processing the patient¿s own tumor in a lab to extract and grow specialized white cells called lymphocytes that may attack their tumor. LN-145 is an investigational drug. Investigational means that it has not been approved by the Food and Drug Administration (FDA). Other drugs used in this study although they may be approved for other conditions may be considered investigational in this study.
Primary Objectives: - To evaluate the safety and tolerability of lymphodepletion, LN-145, and IL-2 in patients with recurrent and/or metastatic cervical carcinoma. - To evaluate the efficacy of therapy using the overall response rate (ORR) in patients with recurrent and/or metastatic cervical carcinoma. Secondary Objectives: - To evaluate other efficacy parameters such as complete response (CR) rate, the duration of response (DOR), progression-free survival (PFS), and overall survival (OS) in patients with recurrent and/or metastatic cervical carcinoma. Exploratory Objectives: - To explore persistence of TILs and immune correlates of response, survival, toxicity of the treatment.
Fluconazole (); IL-2 (Interleukin-2); LN-145 (); MESNA (); Neupogen (filgrastim); Pembrolizumab (Keytruda); cyclophosphamide (); cytoxan (cyclophosphamide); filgrastim (); fludarabine (Fludarabine phosphate)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.